tirzepatide clinicaltrials gov Highlighting 3 ongoing clinical trials of GLP-1 medications in breast and endometrial cancer. 1. FITWISE: for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/​HER2 Negative Breast Cancer 2. Tirzepatide Weight Loss Tirzepatide and autoimmune disease: what

Based on Phase 2 safety data (Jastreboff et al., NEJM 2023), common early adverse effects reported include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea or constipation Reduced appetite Mild fatigue or dizziness These effects are consistent with the GLP-1 receptor agonist class and typically reflect the gut's adaptation to altered gastric emptying and hormonal signalling

Others respond dramatically better to tirzepatide

It typically resolves within 2 to 3 weeks of continued use

Patient safety comes first, not the sales numbers

Eligibility for Ongoing Maintenance Treatment Before approving ongoing maintenance treatment or restarting medication following a treatment break, our clinicians will complete the necessary clinical and safety assessments to confirm that treatment remains safe, clinically appropriate, and suitable for you

Our stages of a bruise picture guide helps you track your recovery visually